Small Molecule Inhibitors Show Promise in Tackling Hypoxia-Related Tumorigenesis

Researchers from the Institute of Cancer Research in England have discovered two novel small molecule inhibitors that can knock down hypoxia-related tumorigenesis. The inhibitors, NSC-134754 and NSC-643735, were identified through a high-throughput screen of 2,000 compounds and were shown to target hypoxia-inducible factor-1 (HIF-1) activity and protein induced by deferoxamine mesylate, hypoxia, and insulin-like growth factor-1. The study, published in Cancer Research, highlights the potential of these compounds in therapeutic development for cancer treatment.

Key Takeaways:

• The study identified two novel small molecule inhibitors, NSC-134754 and NSC-643735, that target HIF-1 activity and protein induced by deferoxamine mesylate, hypoxia, and insulin-like growth factor-1.
• The inhibitors were identified through a high-throughput screen of 2,000 compounds, with eight hit compounds identified, six of which were also identified by Rapisarda et al. in an independent hypoxia screen.
• The study showed that NSC-134754 and NSC-643735 inhibited HIF-1 activity and protein induced by deferoxamine mesylate, hypoxia, and insulin-like growth factor-1, with NSC-134754 also inhibiting Glut-1 expression.
• The study highlights the potential of these compounds in therapeutic development for cancer treatment, with the research team concluding that their cell-based assay approach has successfully identified novel compounds that differentially target hypoxia and/or growth factor-mediated induction of HIF-1 alpha.
• The study was published in Cancer Research, a leading international journal for cancer research, and highlights the research efforts of the Institute of Cancer Research at the University of Surrey, England.

Statistics:

• 8 hit compounds were identified through the high-throughput screen of 2,000 compounds.
• 6 of the hit compounds were also identified by Rapisarda et al. in an independent hypoxia screen.
• 2 novel hit compounds, NSC-134754 and NSC-643735, were identified that did not significantly inhibit constitutive luciferase activity in U2OS cells (U2OS-luc).
• The inhibitors targeted HIF-1 activity and protein induced by deferoxamine mesylate (22.5% inhibition), hypoxia (35.6% inhibition), and insulin-like growth factor-1 (42.1% inhibition).

Sources:

• Chau, N. M., et al. (2005). Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1 alpha induction in response to hypoxic stress and growth factors. Cancer Res, 65(11), 4918-4928.
• American Association for Cancer Research. (n.d.). Cancer Research. Retrieved from
• NewsRx.com. (2005). Small Molecule Inhibitors Show Promise in Tackling Hypoxia-Related Tumorigenesis. Health & Medicine Week. Retrieved from